Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Characterization of Organelle Motility in Human RPE Cells Across the Macula with Adaptive Optics OCT
Author Affiliations & Notes
  • Somayyeh Soltanian-Zadeh
    US Food and Drug Administration, Silver Spring, Maryland, United States
  • Samira Aghayee
    US Food and Drug Administration, Silver Spring, Maryland, United States
  • Anant Agrawal
    US Food and Drug Administration, Silver Spring, Maryland, United States
  • Osamah Saeedi
    University of Maryland Baltimore, Baltimore, Maryland, United States
  • Zhuolin Liu
    US Food and Drug Administration, Silver Spring, Maryland, United States
  • Daniel Xavier Hammer
    US Food and Drug Administration, Silver Spring, Maryland, United States
  • Footnotes
    Commercial Relationships   Somayyeh Soltanian-Zadeh None; Samira Aghayee None; Anant Agrawal None; Osamah Saeedi None; Zhuolin Liu Indiana University, Code P (Patent), US FDA, Code P (Patent); Daniel Hammer US FDA, Code P (Patent)
  • Footnotes
    Support  FDA Critical Path Initiative
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3348. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Somayyeh Soltanian-Zadeh, Samira Aghayee, Anant Agrawal, Osamah Saeedi, Zhuolin Liu, Daniel Xavier Hammer; Characterization of Organelle Motility in Human RPE Cells Across the Macula with Adaptive Optics OCT. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3348.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate regional dependence of retinal pigment epithelium (RPE) organelle motility in healthy human eyes across the macula.

Methods : Three healthy participants (S1-S3) were imaged with the FDA 1060 nm 3.4 MHz Fourier-domain mode-locked-adaptive optics – optical coherence tomography (AO-OCT) system. 2°×2° field of view AO-OCT volumes were collected from the fovea to 12° temporal retina in steps of 1.5° (9 total locations), with the system focus set to the photoreceptor (PR)-RPE complex. At each retinal location, three 10 s videos (20 volumes/video; 0.5 s interval) were acquired to capture the organelle motility speckle decorrelation. Postprocessing included registration of the AO-OCT volumes to reference volumes selected from each of the three video recordings and manual selection of RPE cells. The temporal decorrelation function of each RPE cell, defined by a Voronoi patch, was calculated and normalized to the PR which has a relatively stable temporal correlation. Organelle motility was characterized as the time constant of the fitted exponential decay function to the decorrelation curve.

Results : The RPE cell mosaics were resolved in all locations of the three subjects. The exponential fit to the decorrelation function resulted in average time constants of 6.6 ± 0.9, 7.1 ± 0.8, and 9.2 ± 1.8 s across the macula in S1, S2, and S3, respectively. While the average decay time constant differed between subjects, for subjects S1 and S2, the variation in the estimated values across the macula was small. Subject S3 exhibited the highest variation, which was primarily caused by the higher estimated decay time at the fovea compared to other locations.

Conclusions : RPE organelle motility can be characterized as the time the speckle field takes to decorrelate using high speed AO-OCT. The results in healthy participants indicate low variability in RPE organelle motility across the macula. As diseased RPE cells have been shown to exhibit abnormal organelle motility, we expect that future investigations on diseased eyes will reflect changes in the measured time constant at affected regions. Further investigations on a larger group of healthy subjects will establish a normative baseline for the adoption of RPE organelle motility as a clinically relevant functional biomarker of retinal degenerative diseases.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×